{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:37:51Z","timestamp":1787726271206,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Aim of this study was to evaluate the efficacy of switching treatment to faricimab in neovascular age-related macular degeneration (nAMD) from other anti-VEGF agents. Fifty-eight eyes of fifty-one patients with nAMD and a full upload series of four faricimab injections were included. Demographic data, multimodal imaging and treatment parameters were recorded. The primary outcome measures were changes in central subfield thickness (CST) and subfoveal choroidal thickness (SFCT). A subgroup analysis was performed for eyes with prior ranibizumab (R) or aflibercept (A) treatment. Mean injection intervals before and after switching were comparable (33.8\u2009\u00b1\u200911.2 vs. 29.3\u2009\u00b1\u20092.6\u00a0days;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.08). Mean CST of 361.4\u2009\u00b1\u2009108.1\u00a0\u00b5m prior to switching decreased significantly to 318.3\u2009\u00b1\u200997.7\u00a0\u00b5m (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01) after the third faricimab injection, regardless of prior anti-VEGF treatment (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01). Although SFCT slightly improved for the whole cohort from 165.8\u2009\u00b1\u200976.8\u00a0\u00b5m to 161.0\u2009\u00b1\u200982,8\u00a0\u00b5m (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.029), subgroup analysis did not confirm this positive effect (subgroup R:\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.604; subgroup A:\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.306). In patients with a suboptimal response to aflibercept or ranibizumab in nAMD, farcimab can improve CST and slightly improve or maintain SFCT. Further prospective randomized trials are warranted.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-59632-0","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T06:03:04Z","timestamp":1714111384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration"],"prefix":"10.1038","volume":"14","author":[{"given":"Franziska","family":"Eckardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lorger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hafner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian Elias","family":"Klaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schworm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Christian","family":"Kreutzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried Georg","family":"Priglinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Siedlecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"issue":"7","key":"59632_CR1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley, M. Faricimab: first approval. Drugs 82(7), 825\u2013830 (2022).","journal-title":"Drugs"},{"issue":"1","key":"59632_CR2","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1038\/s41598-020-64901-9","volume":"10","author":"J Siedlecki","year":"2020","unstructured":"Siedlecki, J. et al. Impact of sub-retinal fluid on the long-term incidence of macular atrophy in neovascular age-related macular degeneration under treat & extend anti-vascular endothelial growth factor inhibitors. Sci. Rep. 10(1), 8036 (2020).","journal-title":"Sci. Rep."},{"issue":"21","key":"59632_CR3","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.3390\/ijms21218242","volume":"21","author":"F Ricci","year":"2020","unstructured":"Ricci, F. et al. Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches. Int. J. Mol. Sci. 21(21), 8242 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"82","key":"59632_CR4","doi-asserted-by":"publisher","first-page":"100906","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"1","author":"PS Mettu","year":"2021","unstructured":"Mettu, P. S., Allingham, M. J. & Cousins, S. W. Incomplete response to Anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities. Progr. Retinal Eye Res. 1(82), 100906 (2021).","journal-title":"Progr. Retinal Eye Res."},{"issue":"9","key":"59632_CR5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth, U. et al. Guidelines for the management of neovascular age-related macular degeneration by the European society of retina specialists (EURETINA). British J. Ophthalmol. 98(9), 1144\u20131167 (2014).","journal-title":"British J. Ophthalmol."},{"issue":"8","key":"59632_CR6","doi-asserted-by":"publisher","first-page":"e0272301","DOI":"10.1371\/journal.pone.0272301","volume":"17","author":"S Ozdemir","year":"2022","unstructured":"Ozdemir, S. et al. Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration. PLoS ONE 17(8), e0272301. https:\/\/doi.org\/10.1371\/journal.pone.0272301 (2022).","journal-title":"PLoS ONE"},{"key":"59632_CR7","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.2147\/OPTH.S231801","volume":"4","author":"AM Khanani","year":"2021","unstructured":"Khanani, A. M. et al. Angiopoietins as potential targets in management of retinal disease. Clin. Ophthalmol. 4, 3747\u20133755 (2021).","journal-title":"Clin. Ophthalmol."},{"issue":"9","key":"59632_CR8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrd.2016.278","volume":"16","author":"P Saharinen","year":"2017","unstructured":"Saharinen, P., Eklund, L. & Alitalo, K. Therapeutic targeting of the angiopoietin\u2013TIE pathway. Nat. Rev. Drug Disc. 16(9), 635\u2013661 (2017).","journal-title":"Nat. Rev. Drug Disc."},{"issue":"10326","key":"59632_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier, J. S. et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399(10326), 729\u2013740 (2022).","journal-title":"Lancet"},{"issue":"5","key":"59632_CR10","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/pharmaceutics15051413","volume":"15","author":"L Ferro Desideri","year":"2023","unstructured":"Ferro Desideri, L., Traverso, C. E., Nicol\u00f2, M. & Munk, M. R. Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration. Pharmaceutics 15(5), 1413 (2023).","journal-title":"Pharmaceutics"},{"issue":"9","key":"59632_CR11","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","volume":"138","author":"AM Khanani","year":"2020","unstructured":"Khanani, A. M. et al. Efficacy of every four monthly and quarterly dosing of faricimab vERUSUs ranibizumab in neovascular age-related macular degeneration: the stairway phase 2 randomized clinical trial. JAMA Ophthalmol. 138(9), 964\u2013972 (2020).","journal-title":"JAMA Ophthalmol."},{"issue":"9","key":"59632_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","volume":"138","author":"J Sahni","year":"2020","unstructured":"Sahni, J. et al. Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the avenue phase 2 randomized clinical trial. JAMA Ophthalmol. 138(9), 955\u2013963 (2020).","journal-title":"JAMA Ophthalmol."},{"key":"59632_CR13","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2147\/OPTH.S409822","volume":"31","author":"EH Leung","year":"2023","unstructured":"Leung, E. H. et al. Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration. Clin. Ophthal. 31, 1287\u20131293 (2023).","journal-title":"Clin. Ophthal."},{"issue":"8","key":"59632_CR14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.oret.2020.03.010","volume":"4","author":"I Maruko","year":"2020","unstructured":"Maruko, I. et al. 2-Year outcomes of treat-and-extend intravitreal aflibercept for exudative age-related macular degeneration: a prospective study. Ophthalmol. Retina 4(8), 767\u2013776 (2020).","journal-title":"Ophthalmol. Retina"},{"issue":"6","key":"59632_CR15","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.ophtha.2015.02.009","volume":"122","author":"JJ Arnold","year":"2015","unstructured":"Arnold, J. J. et al. Two-year outcomes of \u201ctreat and extend\u201d intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology 122(6), 1212\u20131219 (2015).","journal-title":"Ophthalmology"},{"issue":"5","key":"59632_CR16","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen, A. M. et al. Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye 35(5), 1305\u20131316 (2021).","journal-title":"Eye"},{"issue":"15","key":"59632_CR17","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga, P. E. et al. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye 37(15), 3282\u20133289 (2023).","journal-title":"Eye"},{"issue":"10","key":"59632_CR18","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1007\/s00417-023-06116-y","volume":"261","author":"H Matsumoto","year":"2023","unstructured":"Matsumoto, H., Hoshino, J., Nakamura, K., Nagashima, T. & Akiyama, H. Short-term outcomes of intravitreal faricimab for treatment-naive neovascular age-related macular degeneration. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. 261(10), 2945\u20132952 (2023).","journal-title":"Graefe's Arch. Clin. Exp. Ophthalmol."},{"key":"59632_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.11.015","author":"R Raimondi","year":"2023","unstructured":"Raimondi, R. et al. Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab. Ophthalmol. Retina https:\/\/doi.org\/10.1016\/j.oret.2023.11.015 (2023).","journal-title":"Ophthalmol. Retina"},{"issue":"1","key":"59632_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","volume":"8","author":"A Szigiato","year":"2024","unstructured":"Szigiato, A. et al. Short-term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy. Ophthalmol. Retina 8(1), 10\u201317 (2024).","journal-title":"Ophthalmol. Retina"},{"issue":"1","key":"59632_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","volume":"262","author":"K Kataoka","year":"2024","unstructured":"Kataoka, K. et al. 6-Month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. 262(1), 43\u201351 (2024).","journal-title":"Graefe's Arch. Clin. Exp. Ophthalmol."},{"issue":"1","key":"59632_CR22","doi-asserted-by":"publisher","first-page":"21128","DOI":"10.1038\/s41598-023-48190-6","volume":"13","author":"R Tamiya","year":"2023","unstructured":"Tamiya, R. et al. Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration. Sci. Rep. 13(1), 21128 (2023).","journal-title":"Sci. Rep."},{"issue":"4","key":"59632_CR23","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.oret.2023.10.018","volume":"8","author":"SA Pandit","year":"2024","unstructured":"Pandit, S. A. et al. Clinical outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration. Ophthalmol. Retina 8(4), 360\u2013366 (2024).","journal-title":"Ophthalmol. Retina"},{"key":"59632_CR24","first-page":"1","volume":"4","author":"G Grimaldi","year":"2023","unstructured":"Grimaldi, G. et al. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. 4, 1\u20139 (2023).","journal-title":"Graefe's Arch. Clin. Exp. Ophthalmol."},{"issue":"6","key":"59632_CR25","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/eye.2015.48","volume":"29","author":"WM Amoaku","year":"2015","unstructured":"Amoaku, W. M. et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye 29(6), 721\u2013731 (2015).","journal-title":"Eye"},{"issue":"9","key":"59632_CR26","first-page":"1912","volume":"40","author":"A Otani","year":"1999","unstructured":"Otani, A. et al. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest. Ophthal. Visual Sci. 40(9), 1912\u20131920 (1999).","journal-title":"Invest. Ophthal. Visual Sci."},{"issue":"7","key":"59632_CR27","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1167\/iovs.05-1229","volume":"47","author":"M Saint-Geniez","year":"2006","unstructured":"Saint-Geniez, M., Maldonado, A. E. & D\u2019Amore, P. A. VEGF expression and receptor activation in the choroid during development and in the adult. Invest. Ophthal. Vis. Sci. 47(7), 3135\u20133142 (2006).","journal-title":"Invest. Ophthal. Vis. Sci."},{"issue":"7","key":"59632_CR28","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1007\/s12325-022-02129-x","volume":"39","author":"AM Minnella","year":"2022","unstructured":"Minnella, A. M. et al. Choroidal thickness changes after intravitreal aflibercept injections in treatment-na\u00efve neovascular AMD. Adv. Therapy 39(7), 3248\u20133261 (2022).","journal-title":"Adv. Therapy"},{"issue":"1","key":"59632_CR29","doi-asserted-by":"publisher","first-page":"8747","DOI":"10.1038\/s41598-023-35759-4","volume":"13","author":"R Mukai","year":"2023","unstructured":"Mukai, R. et al. 3-Month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci. Rep. 13(1), 8747 (2023).","journal-title":"Sci. Rep."},{"key":"59632_CR30","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00417-015-3221-x","volume":"254","author":"H Kim","year":"2016","unstructured":"Kim, H. et al. Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. 254, 1497\u20131503 (2016).","journal-title":"Graefe's Arch. Clin. Exp. Ophthalmol."},{"key":"59632_CR31","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/OPTH.S424315","volume":"31","author":"RB Rush","year":"2023","unstructured":"Rush, R. B. 1-Year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin. Ophthalmol. 31, 2201\u20132208 (2023).","journal-title":"Clin. Ophthalmol."},{"issue":"15","key":"59632_CR32","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.3390\/jcm12155145","volume":"12","author":"M Kishi","year":"2023","unstructured":"Kishi, M. et al. Short-term outcomes of faricimab treatment in aflibercept-refractory eyes with neovascular age-related macular degeneration. J. Clin. Med. 12(15), 5145 (2023).","journal-title":"J. Clin. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-59632-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-59632-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-59632-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T06:17:22Z","timestamp":1714112242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-59632-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["59632"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-59632-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3947963\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]},"assertion":[{"value":"11 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9600"}}